Biogen Inc is to acquire Nightstar Therapeutics Plc, a gene therapy company spun out from the University of Oxford and financed by Syncona, which has a product in Phase 3 for the treatment of choroideremia, a rare retinal disorder. The US biotech company will pay $25.50 in cash for each share of Nightstar, valuing the company at approximately $800 million.
